◎ Sugi Atlas

Atlas / Disease / Polyp of large intestine

Polyp of large intestine

disease
On this page

Also known as colorectal polyplarge bowel polyplarge intestine polyppolyp of large bowelpolyp of the large bowelpolyp of the large intestine

Summary

Polyp of large intestine (MONDO:0021392) is a disease (an umbrella term covering 6 Mondo subtypes) with 4 cohort genes (37 GWAS associations across 3 studies) and 150 clinical trials. Top therapeutic interventions include indocyanine green acid form, calcitriol, and calcium.

At a glance

  • Umbrella term: 6 Mondo subtypes
  • Cohort genes: 4
  • GWAS associations: 37
  • ClinVar variants: 5
  • Clinical trials: 150

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepolyp of large intestine
Mondo IDMONDO:0021392
ICD-11537826614
NCITC5679
SNOMED CT399505005
UMLSC0949059
MedGen182694
Anatomy (UBERON)UBERON:0000059
Is cancer (heuristic)no

Also known as: colorectal polyp · large bowel polyp · large intestine polyp · polyp of large bowel · polyp of the large bowel · polyp of the large intestine

Data availability: 5 ClinVar variants · 37 GWAS associations (3 studies).

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › polyp › polyp of large intestine

Related subtypes (20): epulis, polyp of middle ear, uterine polyp, intestinal polyp, hyperplastic polyp, nasal cavity polyp, stomach polyp, neoplastic polyp, polyp of ureter, polyp of vagina, polyp of vulva, polyp of external auditory canal, polyp of sphenoidal sinus, polyp of frontal sinus, polyp of maxillary sinus, polyp of gallbladder, polyp of ethmoidal sinus, polyp of vocal cord, gastrointestinal polyp, fibroepithelial polyp

Subtypes (6): appendix hyperplastic polyp, colorectal hamartoma, polyp of rectum, polyp of colon, POLE-related polyposis and colorectal cancer syndrome, POLD1-related polyposis and colorectal cancer syndrome

Genetics & variants

GWAS landscape

37 GWAS associations across 3 studies. Top hits map to 27 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs670723532e-32LAMA5?0.85
rs22935827e-29GREM1, GREM1-AS1?1.16
rs108085562e-22CASC8, POU5F1B, PCAT1, CCAT2?0.88
rs49398271e-20SMAD7?0.91
rs169696814e-20SCG5 - GREM1?1.18
rs7600776e-18THBS3, MTX1?0.85
rs49395671e-17SMAD7?0.9
rs110658281e-15CUX2?0.8
rs15053516e-14ERBB4?1.18
rs123581501e-13RNA5SP299 - LINC02676?0.91
rs778027951e-13VTI1A?1.11
rs727176465e-13FMN1?1.11
rs60553411e-12SRSF10P2 - HSPBAP1P1?0.91
rs100764493e-12PITX1-AS1?0.93
rs561910213e-12BMP5?0.93
rs2002355174e-12LINC00536 - EIF3H?1.14
rs360963331e-10PITX1-AS1?1.09
rs71301733e-10POU2AF2?1.08
rs1411778651e-09CNTN5 - RN7SL222P?1.39
rs352048603e-09METRNL - RPL23AP87?1.08
rs7040173e-09ZMIZ1-AS1?1.08
rs78341643e-09LINC00536 - EIF3H?0.92
rs2011619593e-09EPS15P1 - MRPL42P4?1.07
rs117793526e-09UTP23?1.11
rs49029418e-09SIPA1L1?0.88
rs1410933691e-08LINC02474, LINC01705?1.08
rs1407842202e-08LINC02044, NEPRO-AS1?0.94
rs73169683e-08LINC00393?1.1
rs7086863e-08FUT6 - FUT3?1.07
rs60668253e-08PREX1?0.94

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90432149Jiang Y2023116,382213,325A cross-disorder study to identify causal relationships, shared genetic variants, and genes across 21 digestive disorders.
GCST90093303Hikino K202111,292237,990Genome-wide association study of colorectal polyps identified highly overlapping polygenic architecture with colorectal cancer.
GCST90093301Hikino K20214,447157,226Genome-wide association study of colorectal polyps identified highly overlapping polygenic architecture with colorectal cancer.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR0
Tier 3: regulatory2
Tier 4: intronic/intergenic31

MAF distribution

BucketVariants
common (>=0.05)32
low_freq (0.01-0.05)0
rare (<0.01)0
unknown2

Functional consequences

ConsequenceCount
intron_variant22
intergenic_variant6
non_coding_transcript_exon_variant3
regulatory_region_variant2
missense_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs670723532062365646G>A0.05intron_variantLAMA52e-32Tier 4: intronic/intergenic
rs22935821532718211G>A,C,T0.05non_coding_transcript_exon_variantGREM1, GREM1-AS17e-29Tier 4: intronic/intergenic
rs108085568127400902C>T0.05non_coding_transcript_exon_variantCASC8, POU5F1B, PCAT1, CCAT22e-22Tier 4: intronic/intergenic
rs49398271848927093T>A,C0.05intron_variantSMAD71e-20Tier 4: intronic/intergenic
rs169696811532700910C>T0.05regulatory_region_variantSCG5 - GREM14e-20Tier 3: regulatory
rs7600771155208991T>A,C,G0.05missense_variantTHBS3, MTX16e-18Tier 1: coding
rs49395671848925503G>A0.05intron_variantSMAD71e-17Tier 4: intronic/intergenic
rs1106582812111191585C>A,T0.05intron_variantCUX21e-15Tier 4: intronic/intergenic
rs15053512212384825C>T0.05intron_variantERBB46e-14Tier 4: intronic/intergenic
rs12358150108693781C>T0.05intergenic_variantRNA5SP299 - LINC026761e-13Tier 4: intronic/intergenic
rs7780279510112505312T>C0.05intron_variantVTI1A1e-13Tier 4: intronic/intergenic
rs727176461532796431T>A0.05intron_variantFMN15e-13Tier 4: intronic/intergenic
rs6055341207863756G>A,C,T0.05intergenic_variantSRSF10P2 - HSPBAP1P11e-12Tier 4: intronic/intergenic
rs100764495135119588C>T0.05intron_variantPITX1-AS13e-12Tier 4: intronic/intergenic
rs56191021655848568C>T0.05intron_variantBMP53e-12Tier 4: intronic/intergenic
rs2002355178116618774CG>Cintergenic_variantLINC00536 - EIF3H4e-12Tier 4: intronic/intergenic
rs360963335135114972T>A,C,G0.05intron_variantPITX1-AS11e-10Tier 4: intronic/intergenic
rs713017311111283347A>C,T0.05intron_variantPOU2AF23e-10Tier 4: intronic/intergenic
rs14117786511100525884A>Cregulatory_region_variantCNTN5 - RN7SL222P1e-09Tier 3: regulatory
rs352048601783095585C>G,T0.05intron_variantMETRNL - RPL23AP873e-09Tier 4: intronic/intergenic
rs7040171079059375A>G0.05intron_variantZMIZ1-AS13e-09Tier 4: intronic/intergenic
rs78341648116632223A>C,G0.05intergenic_variantLINC00536 - EIF3H3e-09Tier 4: intronic/intergenic
rs201161959746825360T>A,C,G0.05intron_variantEPS15P1 - MRPL42P43e-09Tier 4: intronic/intergenic
rs117793528116801302G>A,T0.05intron_variantUTP236e-09Tier 4: intronic/intergenic
rs49029411471633247A>G,T0.05intron_variantSIPA1L18e-09Tier 4: intronic/intergenic
rs1410933691221975917A>C,G0.05intron_variantLINC02474, LINC017051e-08Tier 4: intronic/intergenic
rs1407842203113155787CA>C,CAA,CAAA0.05intron_variantLINC02044, NEPRO-AS12e-08Tier 4: intronic/intergenic
rs73169681373417325T>C,G0.05intron_variantLINC003933e-08Tier 4: intronic/intergenic
rs708686195840608C>T0.05intergenic_variantFUT6 - FUT33e-08Tier 4: intronic/intergenic
rs60668252048723580A>G,T0.05intron_variantPREX13e-08Tier 4: intronic/intergenic

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

3 uncertain significance, 1 pathogenic/likely pathogenic, 1 benign

ClinVarVariant (HGVS)GeneClassificationReview
127838NM_001048174.2(MUTYH):c.1350GGA[1] (p.Glu452del)MUTYHPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
26789946;XY;t(3;4)(q25.3;q21.3)Uncertain significancecriteria provided, single submitter
655283NM_000051.4(ATM):c.9152G>A (p.Gly3051Glu)C11orf65Uncertain significancecriteria provided, multiple submitters, no conflicts
523433NM_000501.4(ELN):c.898A>T (p.Thr300Ser)ELNUncertain significancecriteria provided, multiple submitters, no conflicts
231485NM_000546.6(TP53):c.1060C>A (p.Gln354Lys)TP53Benignreviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 26 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
TP53Orphanet:1333Familial pancreatic carcinoma
TP53Orphanet:145Hereditary breast and/or ovarian cancer syndrome
TP53Orphanet:1501Adrenocortical carcinoma
TP53Orphanet:210159Adult hepatocellular carcinoma
TP53Orphanet:251576Gliosarcoma
TP53Orphanet:251579Giant cell glioblastoma
TP53Orphanet:251899Choroid plexus carcinoma
TP53Orphanet:2807Papilloma of choroid plexus
TP53Orphanet:293199Pleomorphic rhabdomyosarcoma
TP53Orphanet:3318Essential thrombocythemia
TP53Orphanet:524Li-Fraumeni syndrome
TP53Orphanet:52688Myelodysplastic syndrome
TP53Orphanet:585909B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53Orphanet:667662Breast implant-associated anaplastic large cell lymphoma
TP53Orphanet:668Osteosarcoma
TP53Orphanet:67038B-cell chronic lymphocytic leukemia
TP53Orphanet:70573Small cell lung cancer
TP53Orphanet:96253Cushing disease
TP53Orphanet:99756Alveolar rhabdomyosarcoma
TP53Orphanet:99757Embryonal rhabdomyosarcoma
ELNOrphanet:3193Supravalvular aortic stenosis
ELNOrphanet:90348Autosomal dominant cutis laxa
ELNOrphanet:904Williams syndrome
ELNOrphanet:91387Familial thoracic aortic aneurysm and aortic dissection
MUTYHOrphanet:247798MUTYH-related polyposis
MUTYHOrphanet:440437Familial colorectal cancer Type X

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence4

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TP53HGNC:11998ENSG00000141510P04637Cellular tumor antigen p53clinvar
C11orf65HGNC:28519ENSG00000166323Q8NCR3Protein MFIclinvar
ELNHGNC:3327ENSG00000049540P15502Elastinclinvar
MUTYHHGNC:7527ENSG00000132781Q9UIF7Adenine DNA glycosylaseclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TP53Cellular tumor antigen p53Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
C11orf65Protein MFIActs as an inhibitor of mitochondrial fission.
ELNElastinMajor structural protein of tissues such as aorta and nuchal ligament, which must expand rapidly and recover completely.
MUTYHAdenine DNA glycosylaseInvolved in oxidative DNA damage repair.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor12.1×0.404
Other/Unknown31.3×0.404

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TP53Transcription factornop53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
C11orf65Other/Unknownno
ELNOther/UnknownnoTropoelastin
MUTYHOther/UnknownnoNUDIX_hydrolase_dom, HhH_motif, HhH-GPD_domain

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)4
unknown0

Top tissues across cohort

TissueCohort genes
ganglionic eminence1
tendon of biceps brachii1
ventricular zone1
left testis1
right testis1
sperm1
ascending aorta1
descending thoracic aorta1
thoracic aorta1
cerebellar cortex1
cerebellar hemisphere1
right hemisphere of cerebellum1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TP53223ubiquitousmarkerventricular zone, ganglionic eminence, tendon of biceps brachii
C11orf65163ubiquitousmarkersperm, left testis, right testis
ELN227broadmarkerdescending thoracic aorta, ascending aorta, thoracic aorta
MUTYH134ubiquitousmarkercerebellar hemisphere, cerebellar cortex, right hemisphere of cerebellum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TP5322,736
ELN2,692
MUTYH1,815
C11orf65312

Structural data

PDB: 2 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
TP53P04637313
MUTYHQ9UIF73

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
C11orf65Q8NCR374.69
ELNP1550236.20

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 54. Enrichment computed across 4 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Defective MUTYH substrate binding13806.7×0.005MUTYH
Defective MUTYH substrate processing13806.7×0.005MUTYH
Loss of function of TP53 in cancer due to loss of tetramerization ability13806.7×0.005TP53
Regulation of TP53 Expression11903.3×0.007TP53
Transcriptional activation of cell cycle inhibitor p211951.7×0.011TP53
Activation of NOXA and translocation to mitochondria1634.4×0.012TP53
RUNX3 regulates CDKN1A transcription1543.8×0.012TP53
PI5P Regulates TP53 Acetylation1423.0×0.012TP53
Activation of PUMA and translocation to mitochondria1380.7×0.012TP53
Displacement of DNA glycosylase by APEX11346.1×0.012MUTYH
TP53 Regulates Transcription of Caspase Activators and Caspases1317.2×0.012TP53
TP53 Regulates Transcription of Death Receptors and Ligands1317.2×0.012TP53
Urea cycle1292.8×0.012TP53
Regulation of TP53 Activity through Association with Co-factors1271.9×0.012TP53
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain1253.8×0.012TP53
Stabilization of p531253.8×0.012TP53
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest1237.9×0.012TP53
Formation of Senescence-Associated Heterochromatin Foci (SAHF)1223.9×0.012TP53
Zygotic genome activation (ZGA)1223.9×0.012TP53
Regulation of NF-kappa B signaling1211.5×0.012TP53
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest1200.3×0.012TP53
SUMOylation of transcription factors1190.3×0.012TP53
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release1181.3×0.012TP53
Regulation of TP53 Activity through Methylation1181.3×0.012TP53
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain1173.0×0.012TP53
Regulation of TP53 Activity through Acetylation1152.3×0.014TP53
Pyroptosis1141.0×0.014TP53
Elastic fibre formation1112.0×0.017ELN
Oncogene Induced Senescence1112.0×0.017TP53
Molecules associated with elastic fibres1102.9×0.017ELN

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
negative regulation of helicase activity14213.0×0.007TP53
cellular response to actinomycin D14213.0×0.007TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator14213.0×0.007TP53
negative regulation of G1 to G0 transition14213.0×0.007TP53
positive regulation of mitochondrial membrane permeability12106.5×0.007TP53
oligodendrocyte apoptotic process12106.5×0.007TP53
negative regulation of glucose catabolic process to lactate via pyruvate12106.5×0.007TP53
negative regulation of pentose-phosphate shunt12106.5×0.007TP53
obsolete homolactic fermentation11404.3×0.007TP53
signal transduction by p53 class mediator11404.3×0.007TP53
negative regulation of miRNA processing11404.3×0.007TP53
intrinsic apoptotic signaling pathway in response to hypoxia11404.3×0.007TP53
regulation of fibroblast apoptotic process11404.3×0.007TP53
T cell proliferation involved in immune response11053.2×0.007TP53
depurination11053.2×0.007MUTYH
positive regulation of programmed necrotic cell death11053.2×0.007TP53
oxidative stress-induced premature senescence11053.2×0.007TP53
B cell lineage commitment1842.6×0.007TP53
T cell lineage commitment1842.6×0.007TP53
mRNA transcription1842.6×0.007TP53
positive regulation of RNA polymerase II transcription preinitiation complex assembly1842.6×0.007TP53
positive regulation of thymocyte apoptotic process1842.6×0.007TP53
cellular response to UV-C1842.6×0.007TP53
negative regulation of mitochondrial fission1842.6×0.007C11orf65
regulation of mitochondrial membrane permeability involved in apoptotic process1702.2×0.008TP53
obsolete negative regulation of protein targeting to mitochondrion1702.2×0.008C11orf65
viral process1601.9×0.008TP53
mitochondrial DNA repair1601.9×0.008TP53
regulation of cell cycle G2/M phase transition1601.9×0.008TP53
regulation of tissue remodeling1526.6×0.008TP53

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 3

Druggability breadth: 3 of 4 evidence-associated genes (75%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
TP53NITROFURANTOIN

Top cohort targets by molecule count

SymbolMoleculesMax phase
TP531964
C11orf6500
ELN00
MUTYH00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
NITROFURANTOIN4TP53
DIOSMIN4TP53
VERTEPORFIN4TP53
CANDESARTAN CILEXETIL4TP53
DIENESTROL4TP53
CLOTRIMAZOLE4TP53
COLCHICINE4TP53
NABUMETONE4TP53
SALMETEROL XINAFOATE4TP53
AMIODARONE HYDROCHLORIDE4TP53
FURAZOLIDONE4TP53
AMOXAPINE4TP53
RALOXIFENE HYDROCHLORIDE4TP53
NICARDIPINE HYDROCHLORIDE4TP53
SULCONAZOLE NITRATE4TP53
PYRITHIONE ZINC4TP53
LACTIC ACID4TP53
OXYMETHOLONE4TP53
CHLOROXINE4TP53
PROPIOLACTONE4TP53
CLOMIPRAMINE HYDROCHLORIDE4TP53
PHENYL AMINOSALICYLATE4TP53
THIORIDAZINE HYDROCHLORIDE4TP53
AMITRIPTYLINE HYDROCHLORIDE4TP53
ETHOPROPAZINE HYDROCHLORIDE4TP53
MECHLORETHAMINE HYDROCHLORIDE4TP53
ECONAZOLE NITRATE4TP53
TRIFLUPROMAZINE HYDROCHLORIDE4TP53
PROCHLORPERAZINE EDISYLATE4TP53
DEQUALINIUM CHLORIDE4TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
TP53869Binding:775, ADMET:83, Functional:10, Toxicity:1
MUTYH1Functional:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
TP53869

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
NITROFURANTOIN4TP53
DIOSMIN4TP53
VERTEPORFIN4TP53
CANDESARTAN CILEXETIL4TP53
DIENESTROL4TP53
CLOTRIMAZOLE4TP53
COLCHICINE4TP53
NABUMETONE4TP53
SALMETEROL XINAFOATE4TP53
AMIODARONE HYDROCHLORIDE4TP53
FURAZOLIDONE4TP53
AMOXAPINE4TP53
RALOXIFENE HYDROCHLORIDE4TP53
NICARDIPINE HYDROCHLORIDE4TP53
SULCONAZOLE NITRATE4TP53
PYRITHIONE ZINC4TP53
LACTIC ACID4TP53
OXYMETHOLONE4TP53
CHLOROXINE4TP53
PROPIOLACTONE4TP53
CLOMIPRAMINE HYDROCHLORIDE4TP53
PHENYL AMINOSALICYLATE4TP53
THIORIDAZINE HYDROCHLORIDE4TP53
AMITRIPTYLINE HYDROCHLORIDE4TP53
ETHOPROPAZINE HYDROCHLORIDE4TP53
MECHLORETHAMINE HYDROCHLORIDE4TP53
ECONAZOLE NITRATE4TP53
TRIFLUPROMAZINE HYDROCHLORIDE4TP53
PROCHLORPERAZINE EDISYLATE4TP53
DEQUALINIUM CHLORIDE4TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1TP53
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug3C11orf65, ELN, MUTYH

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
C11orf650—
ELN0—
MUTYH1—

Clinical trials & evidence

Clinical trials

Clinical trials: 150.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified144
PHASE42
PHASE31
PHASE21
PHASE11
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01646242PHASE4COMPLETEDCold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps
NCT02887573PHASE4UNKNOWNFree-residue Nutrients for the Bowel Preparation of Colon Capsule Endoscopy
NCT02343601PHASE3COMPLETEDPerioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery
NCT05776381PHASE2NOT_YET_RECRUITINGThe Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp
NCT00298545PHASE1COMPLETEDEffect of Vitamin D and Calcium on Genes in the Colon
NCT03070613EARLY_PHASE1UNKNOWNInvestigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery
NCT04307901Not specifiedRECRUITINGSafety Of ColoRectal Assessment and Tumor Evaluation by Colon Capsule Endoscopy
NCT04824053Not specifiedRECRUITINGEffects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development
NCT05041478Not specifiedRECRUITINGCold Snare Endoscopic Mucosal Resection (EMR) vs Cold EMR With Margin Snare Tip Soft Coagulation (STSC)
NCT05064124Not specifiedRECRUITINGEarly DiAgnosis Real-Time Healthcare System for CANcer Trial
NCT05144152Not specifiedRECRUITINGDiagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)
NCT05612347Not specifiedRECRUITINGColonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT05636085Not specifiedNOT_YET_RECRUITINGClinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma
NCT05877456Not specifiedENROLLING_BY_INVITATIONValidation of the Global Polypectomy Assessment Tool (GPAT)
NCT05988645Not specifiedRECRUITINGPerformance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
NCT06032104Not specifiedRECRUITINGFeasibility and Colorectal Benefits of Pulses Supplementation
NCT06040632Not specifiedACTIVE_NOT_RECRUITINGIMPROVE-pT1: Accurate Allocation of Completion Resection in Early Colorectal Cancer
NCT06067620Not specifiedNOT_YET_RECRUITINGRobotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy
NCT06133387Not specifiedRECRUITINGPARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
NCT06193356Not specifiedRECRUITINGDetection of Endoscopic Resection Scars and Delineation of Recurrence is Trainable
NCT06220149Not specifiedRECRUITINGPost Polypectomy Bleeding. Que Sera, Sera? Whatever Will be, Will be?
NCT06342440Not specifiedRECRUITINGEarly Detection of Advanced Adenomas and Colorectal Cancer
NCT06447012Not specifiedRECRUITINGArtificial Intelligence Development for Colorectal Polyp Diagnosis
NCT06452745Not specifiedRECRUITINGEarly Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
NCT06502704Not specifiedRECRUITINGBile Acids and Microbiome in Early Colorectal Carcinogenesis
NCT06603519Not specifiedENROLLING_BY_INVITATIONImpact of Dietary Intervention on Inflammation and Microbiome Composition Post-Colonoscopy
NCT06629051Not specifiedRECRUITING6-year Follow-up Data After the Berberine Intervention Trial
NCT06715384Not specifiedRECRUITINGEvaluation of a CAM System for Colorectal Polyp Size Measurement
NCT06773832Not specifiedRECRUITINGAI in Predicting Polyp Pathology and Endoscopic Classification
NCT06791408Not specifiedRECRUITINGClinical Study on the Accuracy of Real-time AI-assisted Endocytoscopy in the Diagnosis of Colorectal Diminutive Polyps
NCT06855355Not specifiedENROLLING_BY_INVITATIONCBM588 Reduces Colorectal Polyp Recurrence
NCT06924489Not specifiedNOT_YET_RECRUITINGAdvanced Adenoma Detection With 3D Imaging Device During Colonoscopy
NCT06927258Not specifiedENROLLING_BY_INVITATIONApplication of Changyanning Granule in Endoscopic Resection of Colorectal Polyps
NCT06937047Not specifiedNOT_YET_RECRUITINGEfficacy and Safety of Cold Versus Hot Snare Polypectomy for Removal of 4-10 mm Pedunculated Colorectal Polyps
NCT06957626Not specifiedRECRUITINGDevelopment and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
NCT07005453Not specifiedRECRUITINGAccuracy and Sustainability of SCALE-EYE Evaluation for Measuring Reliable Polyp Size
NCT07314554Not specifiedNOT_YET_RECRUITINGRecurrence After Gastric and Intestinal Polyp Resection
NCT07328308Not specifiedNOT_YET_RECRUITINGDelayed Surveillance Colonoscopy Following Piecemeal EMR
NCT07362524Not specifiedNOT_YET_RECRUITINGAI-Assisted Real-Time Endoscopic Characterization of Diminutive Colorectal Polyps in Non-Academic Hospitals
NCT07389759Not specifiedACTIVE_NOT_RECRUITINGImpact of CADx on Endoscopists’ Histologic Characterization of Diminutive Colorectal Polyps

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
INDOCYANINE GREEN ACID FORM42
CALCITRIOL41
CALCIUM41
MOSAPRIDE33
BLOOD, WHOLE31
SELENIUM31
BERBERINE CHLORIDE11

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 71

This page pulls from 71 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgwasgwas_studyhgncicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptuberonufeatureumlsuniprot